RU2015152175A - Комбинация ro5503781, капецитабина и оксалиплатина для терапии рака - Google Patents
Комбинация ro5503781, капецитабина и оксалиплатина для терапии рака Download PDFInfo
- Publication number
- RU2015152175A RU2015152175A RU2015152175A RU2015152175A RU2015152175A RU 2015152175 A RU2015152175 A RU 2015152175A RU 2015152175 A RU2015152175 A RU 2015152175A RU 2015152175 A RU2015152175 A RU 2015152175A RU 2015152175 A RU2015152175 A RU 2015152175A
- Authority
- RU
- Russia
- Prior art keywords
- day
- chloro
- fluorophenyl
- days
- product according
- Prior art date
Links
- TVTXCJFHQKSQQM-LJQIRTBHSA-N 4-[[(2r,3s,4r,5s)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)pyrrolidine-2-carbonyl]amino]-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1NC(=O)[C@H]1[C@H](C=2C(=C(Cl)C=CC=2)F)[C@@](C#N)(C=2C(=CC(Cl)=CC=2)F)[C@H](CC(C)(C)C)N1 TVTXCJFHQKSQQM-LJQIRTBHSA-N 0.000 title claims 11
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 title claims 4
- 229960001756 oxaliplatin Drugs 0.000 title claims 4
- 238000011275 oncology therapy Methods 0.000 title 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 4
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 229960004117 capecitabine Drugs 0.000 claims 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- -1 ester salt Chemical class 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229940127557 pharmaceutical product Drugs 0.000 claims 2
- 229940126062 Compound A Drugs 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000005059 dormancy Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Dermatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361836899P | 2013-06-19 | 2013-06-19 | |
| US61/836,899 | 2013-06-19 | ||
| PCT/EP2014/062496 WO2014202497A1 (en) | 2013-06-19 | 2014-06-16 | Combination of ro5503781, capecitabine and oxaliplantin for cancer therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2015152175A true RU2015152175A (ru) | 2017-07-24 |
| RU2015152175A3 RU2015152175A3 (enExample) | 2018-04-02 |
Family
ID=50976625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015152175A RU2015152175A (ru) | 2013-06-19 | 2014-06-16 | Комбинация ro5503781, капецитабина и оксалиплатина для терапии рака |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20160129034A1 (enExample) |
| EP (1) | EP3010508B1 (enExample) |
| JP (1) | JP6549107B2 (enExample) |
| KR (1) | KR20160009677A (enExample) |
| CN (1) | CN105263499B (enExample) |
| BR (1) | BR112015030734A2 (enExample) |
| CA (1) | CA2912743A1 (enExample) |
| ES (1) | ES2747073T3 (enExample) |
| MX (1) | MX2015017124A (enExample) |
| PL (1) | PL3010508T3 (enExample) |
| RU (1) | RU2015152175A (enExample) |
| WO (1) | WO2014202497A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021033144A1 (en) * | 2019-08-20 | 2021-02-25 | Intas Pharmaceuticals Ltd. | Oral suspension of capecitabine |
| CN113698435B (zh) * | 2021-08-25 | 2023-09-29 | 中国人民解放军空军军医大学 | 一类含有p53-MDM2抑制剂的四价铂配合物及其制备方法与应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007107543A1 (en) * | 2006-03-22 | 2007-09-27 | Janssen Pharmaceutica N.V. | Inhibitors of the interaction between mdm2 and p53 |
| EP3175853B1 (en) * | 2008-08-04 | 2023-11-01 | Wyeth LLC | Antineoplastic combinations of neratinib and capecitabine |
| US8354444B2 (en) * | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
-
2014
- 2014-06-16 CN CN201480032428.2A patent/CN105263499B/zh not_active Expired - Fee Related
- 2014-06-16 CA CA2912743A patent/CA2912743A1/en not_active Abandoned
- 2014-06-16 WO PCT/EP2014/062496 patent/WO2014202497A1/en not_active Ceased
- 2014-06-16 KR KR1020157035737A patent/KR20160009677A/ko not_active Ceased
- 2014-06-16 EP EP14731223.5A patent/EP3010508B1/en active Active
- 2014-06-16 PL PL14731223T patent/PL3010508T3/pl unknown
- 2014-06-16 JP JP2016520399A patent/JP6549107B2/ja not_active Expired - Fee Related
- 2014-06-16 RU RU2015152175A patent/RU2015152175A/ru not_active Application Discontinuation
- 2014-06-16 BR BR112015030734A patent/BR112015030734A2/pt not_active IP Right Cessation
- 2014-06-16 MX MX2015017124A patent/MX2015017124A/es unknown
- 2014-06-16 ES ES14731223T patent/ES2747073T3/es active Active
- 2014-06-16 US US14/897,416 patent/US20160129034A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2015017124A (es) | 2016-03-07 |
| EP3010508A1 (en) | 2016-04-27 |
| ES2747073T3 (es) | 2020-03-10 |
| BR112015030734A2 (pt) | 2017-07-25 |
| CA2912743A1 (en) | 2014-12-24 |
| EP3010508B1 (en) | 2019-07-24 |
| JP2016521760A (ja) | 2016-07-25 |
| HK1213475A1 (zh) | 2016-07-08 |
| US20160129034A1 (en) | 2016-05-12 |
| JP6549107B2 (ja) | 2019-07-24 |
| KR20160009677A (ko) | 2016-01-26 |
| CN105263499B (zh) | 2019-11-15 |
| CN105263499A (zh) | 2016-01-20 |
| PL3010508T3 (pl) | 2019-12-31 |
| RU2015152175A3 (enExample) | 2018-04-02 |
| WO2014202497A1 (en) | 2014-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2356547C2 (ru) | Способы лечения рака с использованием ингибиторов hdac | |
| RU2014141362A (ru) | Комбинированная терапия пролиферативных нарушений | |
| RU2010133489A (ru) | Применение ингибиторов гамма-секретазы для лечения рака | |
| RU2020107416A (ru) | Комбинация, содержащая палбоциклиб и 6-(2,4-дихлорфенил)-5-[4-[(3s)-1-(3-фторпропил)пиррролидин-3-ил]-8,9-дигидро-7h-бензо[7]аннулен-2-карбоновую кислоту, и ее применение для лечения рака | |
| EA201590166A8 (ru) | Комбинированная терапия для лечения рассеянного склероза | |
| RU2014111069A (ru) | Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение | |
| IL273169B2 (en) | New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild) | |
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| RU2011102797A (ru) | Противоопухолевые комбинации из 4-анилино-3-цианохинолинов и капецитабина | |
| RU2014144254A (ru) | Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение | |
| JOP20210320A1 (ar) | طرق علاج السرطان باستخدام مثبطات prmt5 | |
| CA2435921A1 (en) | Method of cancer therapy | |
| WO2005014032A3 (en) | Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite | |
| RU2017137008A (ru) | Антагонисты толл-подобного рецептора 4 и применение при аутоиммунных заболеваниях печени | |
| RU2020108631A (ru) | Новая вспомогательная терапия для применения в способе лечения рака простаты | |
| JP2016521760A5 (enExample) | ||
| RU2010140888A (ru) | Улучшенные противораковые терапии | |
| RU2015111491A (ru) | Комбинация макроциклического ингибитора протеазы hcv, ненуклеозидного ингибитора hcv и ритонавира | |
| DK2091520T3 (da) | Oral doseringsform omfattende trisubstituerede glycerol-forbindelser | |
| RU2003113210A (ru) | Лечение раковых заболеваний | |
| RU2013126798A (ru) | Комбинированная терапия дексаметазоном | |
| EP3010508B1 (en) | Combination of ro5503781, capecitabine and oxaliplatin for cancer therapy | |
| JP2005509663A5 (enExample) | ||
| RU2015152577A (ru) | Комбинация ro5503781 и капецитабина для лечения рака | |
| JP2017530142A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180723 |